(19)
(11) EP 1 267 945 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.03.2012 Bulletin 2012/12

(45) Mention of the grant of the patent:
05.10.2011 Bulletin 2011/40

(21) Application number: 01926498.5

(22) Date of filing: 30.03.2001
(51) International Patent Classification (IPC): 
A61K 48/00(2006.01)
C12N 5/10(2006.01)
 A61P 35/00(2006.01)
A61K 35/42(2006.01)
(86) International application number:
PCT/US2001/010339
(87) International publication number:
WO 2001/074404 (11.10.2001 Gazette 2001/41)

(54)

GENETICALLY MODIFIED CELLS EXPRESSING A TGF-BETA INHIBITOR, THE CELLS BEING LUNG CANCER CELLS

GENETISCH MODIFIZIERTE ZELLEN, WELCHE EINEN TGF-BETA INHIBITOR EXPRIMIEREN, WOBEI DIE ZELLEN LUNGENKREBSZELLEN SIND

CELLULES GENETIQUEMENT MODIFIEES EXPRIMANT UN INHIBITEUR DE TGF-BETA, CES CELLULES ETANT DES CELLULES CANCEREUSES DU POUMON

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 31.03.2000 US 193497 P

(43) Date of publication of application:
02.01.2003 Bulletin 2003/01

(60) Divisional application:
10178154.0 / 2314322

(73) Proprietor: NovaRx
San Diego, CA 92121 (US)

(72) Inventor:
  • FAKHRAI, Habib
    La Jolla, CA 92037 (US)

(74) Representative: Vossius & Partner 
Siebertstrasse 4
81675 München
81675 München (DE)


(56) References cited: : 
WO-A-93/07906
WO-A-96/25178
 WO-A-96/02143
   
  • FAKHRAI H ET AL: "IMMUNIZATION WITH TGF-82 ANTISENSE GENE MODIFIED TUMOR CELLS ERADICATES INTRACRANIAL GLIOMAS" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 36, 1995, pages 463-E, XP001026154 ISSN: 0197-016X
  • FISCHER J R ET AL: "CONSTITUTIVE SECRETION OF BIOACTIVE TRANSFORMING GROWTH FACTOR BETA1 BY SMALL CELL LUNG CANCER CELL LINES" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 30A, no. 14, 1994, pages 2125-2129, XP000986137 ISSN: 0959-8049
  • NORGAARD P ET AL: "EXPRESSION AND AUTOREGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR MRNA IN SMALL-CELL LUNG CANCER CELL LINES" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 73, no. 9, May 1996 (1996-05), pages 1037-1043, XP001041824 ISSN: 0007-0920
  • ASSELIN-PATUREL C ET AL: "QUANTITATIVE ANALYSIS OF TH1, TH2 AND TGF-BETA1 CYTOKINE EXPRESSIONIN TUMOR, TIL AND PBL OF NON-SMALL CELL LUNG CANCER PATIENTS" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 77, no. 1, 3 July 1998 (1998-07-03), pages 7-12, XP001053407 ISSN: 0020-7136
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).